Výsledky vyhledávání

Akademický článek

Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.

Autor: Wu C; Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486., Raheem IT; Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486., Nahas DD; Discovery Biology, Merck & Co., Inc., West Point, PA 19486., Citron M; Discovery Biology, Merck & Co., Inc., West Point, PA 19486., Kim PS; Office of the President, Merck & Co., Inc., West Point, PA 19486., Montefiori DC; Department of Surgery, Duke University Medical Center, Durham, NC 27710., Ottinger EA; Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486., Hepler RW; Discovery Biology, Merck & Co., Inc., West Point, PA 19486., Hrin R; Discovery Biology, Merck & Co., Inc., West Point, PA 19486., Patel SB; Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486., Soisson SM; Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486., Joyce JG; Process Research and Development, Merck & Co., Inc., West Point, PA 19486.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2024 May 28; Vol. 121 (22), pp. e2317230121. Date of Electronic Publication: 2024 May 20.

Zobrazit plný text záznamu

Akademický článek

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.

Autor: Klupsch K; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Baeriswyl V; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Scholz R; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Dannenberg J; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Santimaria R; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Senn D; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Kage E; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Zumsteg A; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Attinger-Toller I; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., von der Bey U; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., König-Friedrich S; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Dupuy F; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Lembke W; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Albani C; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Wendelspiess S; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Dinkel L; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Saro D; Janssen R&D, Spring House, PA, USA., Hepler RW; Janssen R&D, Spring House, PA, USA., Laszlo GS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Bertschinger J; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland., Brack S; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland. sbrack@ITS.JNJ.com., Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. rwalter@fredhutch.org.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.; Department of Epidemiology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.

Publikováno v: Leukemia [Leukemia] 2019 Mar; Vol. 33 (3), pp. 805-808. Date of Electronic Publication: 2018 Sep 11.

Zobrazit plný text záznamu

Akademický článek

Spectroscopic analysis of chlamydial major outer membrane protein in support of structure elucidation.

Autor: Hepler RW; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Nahas DD; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Lucas B; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Kaufhold R; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Flynn JA; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Galli JD; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Swoyer R; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Wagner JM; Vaccine Process Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Espeseth AS; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Joyce JG; Vaccine Process Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Cook JC; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey., Durr E; Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc., Kenilworth, New Jersey.

Publikováno v: Protein science : a publication of the Protein Society [Protein Sci] 2018 Nov; Vol. 27 (11), pp. 1923-1941.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání